SKYE has been in the news 313% more than usual
Dec 09, 2025, 7:32 PM
-38.22%
What does SKYE do
Skye Bioscience, a San Diego-based biopharmaceutical company, focuses on cannabinoid-based therapeutics for metabolic disorders and inflammation. Its Phase 2 candidates include nimacimab for obesity and SBI-100 OE for glaucoma.
SKYE has been in the news recently: Several law firms, including DJS Law Group and Schall Law Firm, have announced a class action lawsuit against Skye Bioscience, Inc. for allegedly misleading investors regarding its shares during the period from November 4, 2024, to October 3, 2025. These lawsuits claim that misleading statements contributed to a significant drop in the company's share price.
📡️ Health Care
In The News
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
Cashu is the #1 way to stay ahead of the markets, know why your favourite stocks are moving and access valuation signals that smash the market.